Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Foreign Drugmakers Now Getting More GMP Warning Letters Than U.S. Firms

This article was originally published in The Pink Sheet Daily

Executive Summary

For the first time, this fiscal year FDA seems to be on track to send more warning letters to foreign manufacturers of finished pharmaceuticals and APIs than their domestic counterparts.

You may also be interested in...



FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues

FDA could help create several international coalitions to carry out its new globalization plan, which could allow for issue-specific groups focused on individual pharmaceutical sectors.

FDA Continues Aggressive Enforcement as Drug GMP Warning Letters Mount

The Obama administration’s FDA continues to deliver on its promise of swift and aggressive enforcement of drug GMP requirements that it pronounced two years ago.

Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says

Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.

Topics

UsernamePublicRestriction

Register

PS073931

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel